Bendamustine is an anticancer drug approved to treat chronic lymphocytic leukemia and slow-growing non-Hodgkin lymphoma. It works by damaging a cancer cell’s DNA. However, the body has proteins that try to repair the damaged DNA.
ABT-888 is an investigational drug called a PARP inhibitor. It may inhibit the ability of the proteins to repair the DNA, thereby allowing bendamustine to exert its cancer-killing activity and resulting in more cancer shrinkage or slower cancer growth than using bendamustine alone. It is a pill that is taken orally (by mouth).
In this study, researchers want to find the optimal dose of ABT-888 to give with bendamustine in patients with lymphoma, multiple myeloma, and solid tumors that have continued to grow despite prior therapy. In a later part of the study, patients with lymphoma will also receive rituximab, which enhances the effects of bendamustine; however, it is not known if rituximab will enhance the effects of bendamustine and ABT-888 when they are given together.